204 related articles for article (PubMed ID: 8754493)
1. [Treatment with fludarabine of lymphoid neoplasms with low grade malignity resistant to treatment or in relapse].
Briones J; Montserrat E; Urbano-Ispizua A; Esteve J; Colomer D; López-Guillermo A; Bosch F; Hadjieu E; Rozman C
Med Clin (Barc); 1996 Jun; 107(3):86-9. PubMed ID: 8754493
[TBL] [Abstract][Full Text] [Related]
2. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas.
Bremer K
J Cancer Res Clin Oncol; 2002 Nov; 128(11):603-9. PubMed ID: 12458340
[TBL] [Abstract][Full Text] [Related]
3. Alpha-interferon as maintenance drug after initial fludarabine therapy for patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma.
Zinzani PL; Levrero MG; Lauria F; Rondelli D; Zaja F; Russo D; Fanin R; De Rossi G; Mauro FR; Bendandi M; Gozzetti A; Dianzani F; Mandelli F; Tura S
Haematologica; 1994; 79(1):55-60. PubMed ID: 15378949
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia.
Faderl S; Rai K; Gribben J; Byrd JC; Flinn IW; O'Brien S; Sheng S; Esseltine DL; Keating MJ
Cancer; 2006 Sep; 107(5):916-24. PubMed ID: 16832816
[TBL] [Abstract][Full Text] [Related]
5. Fludarabine in lymphoproliferative malignancies: a single-centre experience.
Prabhash K; Vikram GS; Nair R; Sengar M; Gujral S; Bakshi A; Gupta S; Parikh PM
Natl Med J India; 2008; 21(4):171-4. PubMed ID: 19267037
[TBL] [Abstract][Full Text] [Related]
6. [Long-term results with fludarabine monotherapy in chronic lymphocytic leukemia].
Varga F; Lehoczky D; Demeter J
Orv Hetil; 1999 Aug; 140(31):1731-5. PubMed ID: 10463032
[TBL] [Abstract][Full Text] [Related]
7. Fludarabine and prednisone in pretreated and refractory B-chronic lymphocytic leukemia (B-CLL) in advanced stages.
De Rossi G; Mauro FR; Caruso R; Monarca B; Mandelli F
Haematologica; 1993; 78(3):167-71. PubMed ID: 8375746
[TBL] [Abstract][Full Text] [Related]
8. Fludarabine and cyclophosphamide using an attenuated dose schedule is a highly effective regimen for patients with indolent lymphoid malignancies.
Tam CS; Wolf MM; Januszewicz EH; Prince HM; Westerman D; Seymour JF
Cancer; 2004 May; 100(10):2181-9. PubMed ID: 15139062
[TBL] [Abstract][Full Text] [Related]
9. Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy.
Marotta G; Bigazzi C; Lenoci M; Tozzi M; Bocchia M; Lauria F
Haematologica; 2000 Dec; 85(12):1268-70. PubMed ID: 11114133
[TBL] [Abstract][Full Text] [Related]
10. Fludarabine treatment in B-cell chronic lymphocytic leukemia: response, toxicity and survival analysis in 47 cases.
Stelitano C; Morabito F; Kropp MG; Callea V; Iuliano F; Oriana V; Levato D; Nobile F; Molica S; Brugiatelli M
Haematologica; 1999 Apr; 84(4):317-23. PubMed ID: 10190945
[TBL] [Abstract][Full Text] [Related]
11. Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia.
Waselenko JK; Grever MR; Beer M; Lucas MA; Byrd JC
Semin Oncol; 2000 Apr; 27(2 Suppl 5):44-51. PubMed ID: 10877052
[TBL] [Abstract][Full Text] [Related]
12. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population.
Perkins JG; Flynn JM; Howard RS; Byrd JC
Cancer; 2002 Apr; 94(7):2033-9. PubMed ID: 11932906
[TBL] [Abstract][Full Text] [Related]
13. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.
Tam CS; Wolf M; Prince HM; Januszewicz EH; Westerman D; Lin KI; Carney D; Seymour JF
Cancer; 2006 Jun; 106(11):2412-20. PubMed ID: 16649223
[TBL] [Abstract][Full Text] [Related]
14. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.
Tsimberidou AM; Wierda WG; Plunkett W; Kurzrock R; O'Brien S; Wen S; Ferrajoli A; Ravandi-Kashani F; Garcia-Manero G; Estrov Z; Kipps TJ; Brown JR; Fiorentino A; Lerner S; Kantarjian HM; Keating MJ
J Clin Oncol; 2008 Jan; 26(2):196-203. PubMed ID: 18182662
[TBL] [Abstract][Full Text] [Related]
15. Fludarabine in low-grade lymphoma.
Pigaditou A; Rohatiner AZ; Whelan JS; Johnson PW; Ganjoo RK; Rossi A; Norton AJ; Amess J; Lim J; Lister TA
Semin Oncol; 1993 Oct; 20(5 Suppl 7):24-7. PubMed ID: 8235692
[TBL] [Abstract][Full Text] [Related]
16. [Treatment with fludarabine of chronic refractory lymphoid leukemia].
Herrero M; Cabrera JR; Briz M; Forés R; Díez JL; Regidor C; Sanjuán I; Fernández MN
Sangre (Barc); 1995 Apr; 40(2):115-9. PubMed ID: 7784940
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma.
Roberts JD; Smith MR; Feldman EJ; Cragg L; Millenson MM; Roboz GJ; Honeycutt C; Thune R; Padavic-Shaller K; Carter WH; Ramakrishnan V; Murgo AJ; Grant S
Clin Cancer Res; 2006 Oct; 12(19):5809-16. PubMed ID: 17020988
[TBL] [Abstract][Full Text] [Related]
18. [Fludarabine in the treatment of chronic lymphocytic leukemia and other lymphoproliferative disorders].
Pawelski S
Acta Haematol Pol; 1995; 26(3):263-8. PubMed ID: 8525771
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
O'Brien S; Moore JO; Boyd TE; Larratt LM; Skotnicki A; Koziner B; Chanan-Khan AA; Seymour JF; Bociek RG; Pavletic S; Rai KR
J Clin Oncol; 2007 Mar; 25(9):1114-20. PubMed ID: 17296974
[TBL] [Abstract][Full Text] [Related]
20. [Experience with fludarabine treatment and review of the literature].
Telek B; Rejtó L; Kiss A; Batár P; Reményi G; Rák K; Udvardy M
Orv Hetil; 2002 Jun; 143(24):1459-65. PubMed ID: 12138643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]